Journal
JOURNAL OF PROTEOMICS
Volume 74, Issue 12, Pages 2682-2690Publisher
ELSEVIER
DOI: 10.1016/j.jprot.2011.07.028
Keywords
Food and Drug Administration; In vitro diagnostics; Device regulation; Proteomics; Mass spectrometry; Complex tests
Categories
Ask authors/readers for more resources
Issues associated with the translation of complex proteomic biomarkers from discovery to clinical diagnostics have been widely discussed among academic researchers, government agencies, as well as assay and instrumentation manufacturers. Here, we provide an overview of the regulatory framework and type of information that is typically required in order to evaluate in vitro diagnostic tests regulated by the Office of In Vitro Diagnostic Device Evaluation and Safety (OIVD) at the US Food and Drug Administration (FDA), with the focus on some of the issues specific to protein-based complex tests. Technological points pertaining to mass spectrometry platforms and assessment of potential concerns important for assurance of safety and effectiveness of this type of assays when introduced into clinical diagnostic use, as well as general approaches for evaluating the performance of these devices, are discussed. Published by Elsevier B.V.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available